Podcast

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.

In this episode of the In Vivo podcast Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases.

Israeli-American biotech Immunai is mapping the immune system and using AI to predict immune responses to drugs.